Fennec Pharmaceuticals (FENC) Total Current Liabilities (2010 - 2025)
Fennec Pharmaceuticals (FENC) posted Total Current Liabilities of $10.5 million for Q4 2025, up 7.16% on a QoQ basis from $9.8 million in Q3 2025, and up 52.02% year-over-year from $6.9 million in Q4 2024.
Fennec Pharmaceuticals (FENC) Total Current Liabilities (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $10.5 million for Q4 2025.
- Quarterly Total Current Liabilities rose 52.02% year-over-year to $10.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.5 million (up 52.02% YoY) and the FY2025 annual result came in at $10.5 million, up 52.02% from the prior year.
- Total Current Liabilities was $10.5 million for Q4 2025 at Fennec Pharmaceuticals, up from $9.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $10.5 million in Q4 2025 and bottomed at $848000.0 in Q2 2021.
- A 5-year average of $5.4 million and a median of $4.3 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities tumbled 73.42% — and 2022, when it jumped 258.14%.
- Fennec Pharmaceuticals' Total Current Liabilities stood at $1.7 million in 2021, then jumped by 178.66% to $4.6 million in 2022, then jumped by 63.88% to $7.6 million in 2023, then fell by 8.39% to $6.9 million in 2024, then soared by 52.02% to $10.5 million in 2025.
- Business Quant data shows FENC's Total Current Liabilities at $10.5 million in Q4 2025, $9.8 million in Q3 2025, and $8.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn | 10.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.52 Mn |
| Sep 30, 2025 | 9.82 Mn |
| Jun 30, 2025 | 8.41 Mn |
| Mar 31, 2025 | 8.37 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Sep 30, 2024 | 7.44 Mn |
| Jun 30, 2024 | 7.75 Mn |
| Mar 31, 2024 | 9.84 Mn |
| Dec 31, 2023 | 7.55 Mn |
| Sep 30, 2023 | 3.91 Mn |
| Jun 30, 2023 | 3.78 Mn |
| Mar 31, 2023 | 4.02 Mn |
| Dec 31, 2022 | 4.61 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Jun 30, 2022 | 3.04 Mn |
| Mar 31, 2022 | 2.14 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 2.01 Mn |
| Jun 30, 2021 | 848,000.00 |
| Mar 31, 2021 | 2.89 Mn |